CalciMedica Strengthens Leadership Team with Appointment of Stephen Bardin as Chief Financial Officer
CalciMedica (Nasdaq: CALC), a clinical-stage biopharmaceutical company, announced the appointment of Stephen Bardin as Chief Financial Officer, succeeding Daniel Geffken, Interim CFO, upon the filing of the third quarter financial statements. Bardin, who previously served as CFO of atai Life Sciences, brings extensive expertise in capital raising, corporate development, and strategic finance. He has already contributed to CalciMedica's successful public financing and will play a key role in advancing their clinical-stage pipeline, including the CARPO Phase 2b trial in acute pancreatitis and the upcoming KOURAGE Phase 2 trial in acute kidney injury. Bardin's background includes significant roles at BridgeBio Pharma and Myovant Sciences, and he holds an M.B.A. from Stanford and a B.S.E. from Duke University.
CalciMedica (Nasdaq: CALC), una società biopharmaceutica in fase clinica, ha annunciato la nomina di Stephen Bardin come Chief Financial Officer, succedendo a Daniel Geffken, CFO ad interim, in occasione della presentazione dei bilanci finanziari del terzo trimestre. Bardin, che in precedenza ha ricoperto il ruolo di CFO di atai Life Sciences, porta con sé una vasta esperienza nella raccolta di capitali, nello sviluppo aziendale e nelle finanze strategiche. Ha già contribuito al successo del finanziamento pubblico di CalciMedica e avrà un ruolo chiave nell'avanzamento della loro pipeline in fase clinica, compreso lo studio CARPO di Fase 2b per la pancreatite acuta e il prossimo studio KOURAGE di Fase 2 per l'insufficienza renale acuta. L'esperienza di Bardin include ruoli significativi in BridgeBio Pharma e Myovant Sciences, e ha conseguito un M.B.A. presso Stanford e una B.S.E. presso la Duke University.
CalciMedica (Nasdaq: CALC), una empresa biofarmacéutica en etapa clínica, anunció el nombramiento de Stephen Bardin como Director Financiero, sucediendo a Daniel Geffken, CFO interino, tras la presentación de los estados financieros del tercer trimestre. Bardin, quien anteriormente se desempeñó como CFO de atai Life Sciences, aporta una amplia experiencia en levantamiento de capital, desarrollo corporativo y finanzas estratégicas. Ya ha contribuido al financiamiento público exitoso de CalciMedica y desempeñará un papel clave en el avance de su pipeline en etapa clínica, incluyendo el ensayo CARPO de Fase 2b en pancreatitis aguda y el próximo ensayo KOURAGE de Fase 2 en lesión renal aguda. La trayectoria de Bardin incluye roles significativos en BridgeBio Pharma y Myovant Sciences, y posee un M.B.A. de Stanford y un B.S.E. de la Universidad de Duke.
CalciMedica (Nasdaq: CALC), 임상 단계의 생명공학 회사가 Stephen Bardin을 최고재무책임자(CFO)로 임명했다고 발표했습니다. 이는 Daniel Geffken, 임시 CFO가 3분기 재무 제표를 제출하는 것을 계기로 한 것입니다. Bardin은 이전에 atai Life Sciences에서 CFO로 재직하며 자본 조달, 기업 개발 및 전략적 금융에 대한 광범위한 전문성을 가지고 있습니다. 그는 이미 CalciMedica의 성공적인 공공 자금 조달에 기여했으며, 급성 췌장염에 대한 CARPO 2b임상시험 및 급성 신손상에 대한 KOURAGE 2임상시험을 포함하여 임상 단계 파이프라인을 발전시키는 데 중요한 역할을 할 것입니다. Bardin은 BridgeBio Pharma와 Myovant Sciences에서 중요한 역할을 수행했으며, 스탠포드 대학교에서 M.B.A.를, 듀크 대학교에서 B.S.E.를 취득했습니다.
CalciMedica (Nasdaq: CALC), une entreprise biopharmaceutique en phase clinique, a annoncé la nomination de Stephen Bardin au poste de directeur financier, succédant à Daniel Geffken, directeur financier par intérim, lors de la publication des états financiers du troisième trimestre. Bardin, qui a précédemment exercé en tant que directeur financier de atai Life Sciences, apporte une vaste expertise en levée de fonds, développement d'entreprise et finances stratégiques. Il a déjà contribué à la réussite du financement public de CalciMedica et jouera un rôle clé dans l'avancement de leur pipeline en phase clinique, y compris l'essai CARPO de Phase 2b pour la pancréatite aiguë et le prochain essai KOURAGE de Phase 2 pour l'insuffisance rénale aiguë. Le parcours de Bardin comprend des rôles significatifs chez BridgeBio Pharma et Myovant Sciences, et il est titulaire d'un M.B.A. de Stanford et d'un B.S.E. de l'Université de Duke.
CalciMedica (Nasdaq: CALC), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat die Ernennung von Stephen Bardin zum Chief Financial Officer angekündigt. Er folgt auf Daniel Geffken, Interim CFO, nach der Einreichung der Finanzberichte des dritten Quartals. Bardin, der zuvor als CFO von atai Life Sciences tätig war, bringt umfassende Erfahrungen in der Kapitalbeschaffung, Unternehmensentwicklung und strategischen Finanzen mit. Er hat bereits zum erfolgreichen öffentlichen Finanzierung von CalciMedica beigetragen und wird eine Schlüsselrolle bei der Weiterentwicklung ihrer klinischen Pipeline spielen, einschließlich der CARPO Phase 2b-Studie zur akuten Pankreatitis und der bevorstehenden KOURAGE Phase 2-Studie zur akuten Nierenverletzung. Bardins beruflicher Hintergrund umfasst bedeutende Positionen bei BridgeBio Pharma und Myovant Sciences, zudem hat er einen M.B.A. von Stanford und einen B.S.E. von der Duke University.
- Appointment of Stephen Bardin as CFO, bringing extensive capital raising and strategic finance expertise.
- Successful execution of public financing with Bardin's involvement.
- Promising CARPO Phase 2b data in acute pancreatitis, with a positive outlook for the upcoming KOURAGE Phase 2 trial in acute kidney injury.
- Departure of Daniel Geffken, Interim CFO, which may cause concerns about continuity.
"We are delighted to bring Stephen on board. He is a skilled and experienced biotechnology executive who will be invaluable to CalciMedica as we advance our clinical-stage pipeline," said Rachel Leheny Ph.D., Chief Executive Officer of CalciMedica. "Stephen has been advising us on various strategic matters for several months and, most recently, was critical in executing our successful public financing last week. We look forward to his many future contributions as he now joins us full-time."
"CalciMedica has made impressive recent progress, delivering compelling clinical data for large and underserved patient populations," said Mr. Bardin. "The CARPO Phase 2b data in patients with acute pancreatitis announced last month is promising and provides an optimistic readthrough to KOURAGE, CalciMedica's Phase 2 trial in acute kidney injury, which is expected to read out next year. I look forward to working more closely with the team as we advance AKI in the clinic and prepare for a Phase 3 program in AP."
Mr. Bardin most recently served as CFO of atai Life Sciences where he played a key role in the company's investor relations, business development, capital allocation, and financial operations activities. Prior to that, Mr. Bardin spent nearly three years at BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company with a broad pipeline of development programs, where he oversaw a broad range of finance activities and helped raise over
About CalciMedica
CalciMedica is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammatory and immunologic diseases. CalciMedica's proprietary technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases for which there are currently no approved therapies. CalciMedica's lead product candidate Auxora™ has demonstrated positive and consistent clinical results in multiple completed efficacy clinical trials. CalciMedica has announced data for a Phase 2b trial (called CARPO – NCT04681066) in patients with acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS) and completed a Phase 2 trial (called CARDEA – NCT04345614) in patients with COVID pneumonia. The Company is currently conducting a Phase 2 trial (called KOURAGE – NCT06374797) in patients with acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF) with data expected in 2025 and continuing to support the ongoing Phase 1/2 trial (called CRSPA – NCT04195347) in patients with asparaginase-induced pancreatic toxicity (AIPT) with data expected in 2025. CalciMedica was founded by scientists from Torrey Pines Therapeutics and the Harvard CBR Institute for Biomedical Research, and is headquartered in La Jolla, CA. For more information, please visit www.calcimedica.com.
Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for CalciMedica, including statements about CalciMedica's business strategy; the potential benefits of Auxora for the treatment of AP, AKI and AIPT; expected timing for the release of data from its clinical trials; the potential of CalciMedica's proprietary technology to provide therapeutic benefits in other life-threatening inflammatory and immunologic diseases; and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: economic, business, competitive, and/or regulatory factors affecting the business of CalciMedica generally. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption "Risk Factors" in CalciMedica's Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 and other filings CalciMedica makes with the SEC from time to time and available at www.sec.gov. These documents can also be accessed on CalciMedica's web page at ir.calcimedica.com/financials-filings/sec-filings. All forward-looking statements contained in this press release speak only as of the date on which they were made. CalciMedica undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
CalciMedica Contact:
Investors and Media
Argot Partners
Sarah Sutton/Kevin Murphy
calcimedica@argotpartners.com
(212) 600-1902
View original content to download multimedia:https://www.prnewswire.com/news-releases/calcimedica-strengthens-leadership-team-with-appointment-of-stephen-bardin-as-chief-financial-officer-302298169.html
SOURCE CalciMedica, Inc.
FAQ
Who is the new CFO of CalciMedica?
When will Stephen Bardin assume his role as CFO?
What is the recent clinical progress of CalciMedica?
What previous experience does Stephen Bardin bring to CalciMedica?
